Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
														Search
		×
			NIOSH
			NIOSH
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


The National Institute for Occupational Safety and Health (NIOSH)


Facebook
        Twitter
        LinkedIn
        Syndicate





CALCIUM CYANAMIDE								Related Pages
										*OSHA comments from the January 19, 1989 Final Rule on Air Contaminants Project extracted from 54FR2332 et. seq. This rule was remanded by the U.S. Circuit Court of Appeals and the limits are not currently in force.*
**CAS:** 156-62-7; **Chemical Formula:** CaNC=N
OSHA formerly had no limit for calcium cyanamide. The ACGIH has a TLV-TWA of 0.5 mg/m3 for this crystalline gray material. The proposed PEL was an 8-hour TWA of 0.5 mg/m(3, and NIOSH (Ex. 8-47, Table N1) concurs with this limit, which is established in the final rule.
Data regarding the acute toxicity of calcium cyanamide are sparse. The oral LD(50) in rabbits is 1400 mg/kg, and that for rats is 1000 mg/kg (Spencer 1973, as cited in ACGIH 1986/Ex. 1-3, p. 91).
Skin and eye irritation have been reported in rats and rabbits, with significant irritation occurring when 100 mg of calcium cyanamide is placed directly into the eyes of rabbits (Martin 1975, as cited in ACGIH 1986/Ex. 1-3, p. 91). Severe skin irritation developed in rabbits when a paste of this substance was applied to the shaved abdominal skin for 24 hours (Martin 1975, as cited in ACGIH 1986/Ex. 1-3, p. 91). Two of five animals died when the dose was 10 g/kg, but all survived a dose of 5 g/kg.
Most cases of industrial calcium cyanamide poisoning involve primary skin irritation or sensitizing dermatitis. Skin irritation develops in the form of an erythematous rash over the surfaces of the body that are exposed to the substance or those body surfaces irritated by clothing or perspiration. Some individuals develop a macular rash on exposure, and this may progress to the weeping stage. In addition, exposed workers may develop temporary vasomotor disturbances of the upper body, with susceptibility increasing with alcohol intake (Fassett 1963d, as cited in ACGIH 1986/Ex. 1-3, p. 91). Calcium cyanamide is used medically for its Antabuse-like effect, and the maintenance dose in adults is between 50 and 100 mg/day (Hald, Jacobsen, and Larson 1952/Ex. 1-905). No comments, other than NIOSH’s, were received on this substance.
In the final rule, OSHA is establishing an 8-hour TWA PEL of 0.5 mg/m3 for calcium cyanamide. The Agency concludes that this limit will substantially reduce the significant risks of material health impairment in the form of eye and skin irritation, sensitizing dermatitis, and the occurrence of Antabuse-like effects, which were possible at the levels of exposure formerly permitted by the absence of an OSHA limit.
										
							
								Page last reviewed:  September 28, 2011						Content source:  	National Institute for Occupational Safety and Health NIOSH
1988 OSHA PEL Project Documentation
Index of Chemical Names
Index of CAS Numbers Follow NIOSH Facebook
Pinterest
Twitter
YouTube
 NIOSH Homepage NIOSH A-Z
Workplace Safety & Health Topics
Publications and Products
Programs
Contact NIOSH


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue